Objectives: We evaluated the results of surgical treatment
and postoperative radiotherapy and prognostic factors
in patients with primary tongue carcinoma.
Patients and Methods: The study included 60 patients
(31 males, 29 females; median age 54 years; range 22 to
82 years) who underwent surgery and postoperative radiotherapy
for oral tongue cancer. Tumor staging based on
the AJCC-1997 criteria was as follows: stage I (n=1), stage
II (n=21), stage III (n=12), and stage IVA (n=26). Surgery
included hemiglossectomy (n=46, 76%), partial (n=13,
22%) and total (n=1, 2%) glossectomy. Neck dissection
was performed in 47 patients (78%). Radiotherapy dose
was generally 6000 cGy/30 fr. The median follow-up was
51 months (range 5 to 180 months).
Results: The five-year overall and relapse-free survival
rates were 50% and 47%, respectively. Survival at five
years was 70% for stage I-III, and 20% for stage IVA. Most
of the relapses occurred in the first two years after treatment.
Recurrences were encountered in 31 patients
(52%). The median survival after recurrence was eight
months (range 1 to 53 months). In multivariate analyses,
significant prognostic factors for overall survival and
locoregional control were tumor size, stage, N stage,
extracapsular lymph node spread, and total duration of
radiotherapy. Complications were within acceptable limits.
Conclusion: Postoperative radiotherapy should be standard
for patients with stage III and IVA tongue cancer.
FREE FULL TEXTAnahtar Kelimeler: Skuamöz hücreli karsinom; prognoz; radyoterapi;dil neoplazileri.